Next generation inhaled COVID-19 vaccine

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and immune response of a new inhaled vaccine designed to prevent COVID-19 infection. Participants, who must have received at least three doses of an mRNA COVID vaccine, will be randomly assigned to receive either the experimental vaccine or a placebo. The vaccine is administered as a fine mist inhaled directly into the lungs, and participants will undergo follow-up visits for checkups and blood tests over a 24-week period. Additionally, some participants may have lung cells collected for analysis through a bronchoscopy.

Why it matters

Who can join: the full rules

Inclusion criteria:

1. Adults who are 18-65 years old on the day of randomization (day 1)
2. Able to read, write and communicate using the English or French language.
3. Received at least 3 doses of an mRNA COVID vaccine.
4. Individuals of childbearing potential must have a negative pregnancy test prior to vaccination and be willing to practice effective contraception for 8 weeks post-vaccination.
5. Able to understand and comply with protocol requirements and instructions; able to report adverse events; able to attend scheduled study visits and complete required investigations.
6. For participants in the BAL sub-study, Complete Blood Count (CBC) and chemistry (creatinine) within normal limits.
7. For participants in the BAL sub-study, forced expiratory volume in 1 second (FEV1) \> the lower limit of normal (LLN), and FEV1/FVC (forced expiratory volume in 1 second/forced vital capacity) ratio above the LLN.
8. Agree not to enroll in any other intervention studies for the duration of the study where the intervention could be reasonably expected to be associated with adverse events overlapping with the inhaled vaccine or the immune responses being measured.

Exclusion criteria:

1. Failure to provide informed consent.
2. Women who are pregnant or breastfeeding.
3. Have received any recombinant adenoviral-vectored COVID-19 vaccine (AstraZeneca \[Vaxzeria\] or Johnson \& Johnson (Janssen Jcovden).
4. COVID infection (positive PCR or antigen (Ag) test, self-reported or lab documented) within the last 90 days.
5. Last dose of a COVID vaccine administered less than 90 days prior to study entry.
6. Administration of any vaccine within 2 weeks of study entry.
7. Active pulmonary disease diagnosed by a physician including asthma, chronic bronchitis, interstitial lung disease, pulmonary hypertension, lung cancer, cystic fibrosis, or bronchiectasis. Current use of daily inhaled steroids for any condition.
8. Persons with HIV and a detectable HIV viral load (\>20 copies/mL), self-reported or confirmed.
9. Administration of monoclonal antibodies for treatment of COVID-19 infection within 3 months.
10. Moderately or severely immunocompromised (e.g. transplant recipients/CAR-T cell therapy, currently on chemotherapy for cancer or on potent immunosuppressant therapies e.g. rituximab or high dose steroids \[\>30 mg of prednisone equivalent daily\], or moderate or severe primary immunodeficiency syndrome).
11. History of severe reaction to previous COVID vaccination (e.g. hives, difficulty breathing, high fever, seizures, myocarditis, pericarditis)).
12. Potential contraindication to COVID vaccination (e.g. venous or arterial thrombosis with thrombocytopenia after vaccination, history of cerebral venous thrombosis with thrombocytopenia, history of heparin induced thrombocytopenia, history of myocarditis or pericarditis).
13. Known allergy to vaccine components or previous receipt of any experimental adenovirus-vector vaccine by the aerosol route.
14. Enrolment in any clinical trial of experimental treatment for COVID infection within 90 days.
15. For participants in the BAL sub-study, any health-related condition for which study bronchoscopy is contraindicated.
16. For participants in the BAL sub-study, current use of anticoagulants.

Where it's running

• Canadian Center for Vaccinology, Dalhousie University
  Halifax, Nova Scotia, Canada Recruiting
• Health Sciences Centre
  Hamilton, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Fiona Smaill — McMaster University
• Study coordinator: Marilyn Swinton
• Email: swinton@mcmaster.ca
• Phone: 289-244-3997

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ibuzatrelvir alone or with remdesivir for severely immunocompromised adults with COVID-19

  This will test whether ibuzatrelvir, taken alone or together with remdesivir, helps severely immunocompromised adults who recently developed COVID-19 symptoms.

  Recruiting at 148 sites Phase 3 Pfizer · Canoga Park, California and 158 other locations · NCT07013474

• Evaluating COVID-19 immunity and reinfection risk

  This study is testing how well COVID-19 vaccines and previous infections protect medical staff from getting reinfected with the virus over 48 weeks.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT05774093

• Understanding the benefits of human milk on infant and child health

  This study is trying to see how breast milk affects the health of babies and children by collecting milk samples and health information from breastfeeding mothers.

  Recruiting University of California, San Diego · San Diego, California · NCT05553743

• Examining how COVID-19 changed pulmonary procedures

  This study looks at how doctors who treat lung conditions changed their procedures and staffing during the COVID-19 pandemic to see what worked best.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT05022446

• Analyzing immune responses to COVID-19 through sample collection

  This study is testing how the immune system reacts to COVID-19 by collecting samples from people who have had the virus and those who haven't, to see what this means for their health.

  Recruiting National Institutes of Health Clinical Center (CC) · Rockville, Maryland · NCT04582903

• Impact of COVID-19 on young cancer patients and survivors

  This study is trying to see how the COVID-19 pandemic has affected the mental, physical, and social well-being of young cancer patients and survivors aged 18 to 39.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT04551378

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.